Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214289 | 1.00 | KMT2A (0.48) | KMT2AMEN1TDP1CYP19A1POLB | |
| SCHEMBL2169975 | 0.79 | MAPT (0.51) | KMT2ACYP19A1HSP90AA1LMNATP53 | |
| SCHEMBL2215950 | 0.79 | MAPT (0.51) | KMT2ACYP19A1HSP90AA1LMNATP53 | |
| SCHEMBL1964298 | 0.78 | MEN1 (0.57) | KMT2AMEN1TDP1CYP19A1POLB | |
| SCHEMBL11369815 | 0.77 | KMT2A (0.77) | KMT2AMEN1TDP1CYP19A1POLB | |
| SCHEMBL2192813 | 0.77 | KMT2A (0.50) | KMT2AMEN1TDP1CYP19A1POLB | |
| SCHEMBL13447835 | 0.77 | MEN1 (0.56) | KMT2AMEN1TDP1CYP19A1POLB | |
| SCHEMBL12437868 | 0.77 | KMT2A (0.52) | KMT2AMEN1TDP1CYP19A1POLB | |
| SCHEMBL10769481 | 0.76 | KMT2A (0.52) | KMT2AMEN1TDP1POLBHSP90AA1 | |
| SCHEMBL1964353 | 0.76 | MEN1 (0.54) | KMT2AMEN1TDP1CYP19A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346835-A1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS, THEIR USE AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20110177950-A1 | Imidazole and Triazole Compounds, Their Use and Agents Containing the Same | BASF SE (DE) | 2011-07-21 | — | — | US | disclosed |
| EP-2334650-A1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS, THEIR USE AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010031843-A1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS, THEIR USE AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010031848-A1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS, THEIR USE AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177950-A1 | Imidazole and Triazole Compounds, Their Use and Agents Containing the Same | COX4I1, CYP2C19, CYP3A43 | KMT2A 1323/4885MEN1 986/4885TDP1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.